Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Incyte Corp. Stock , INCY

65.19 -0.68 -1.03%
03:59:59 PM EDT 7/22/2024 BTT
Plus500. 80% of retail CFD accounts lose money
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 07/19/2024 the closing price of the Incyte Corp. share was $65.87 on BTT. Compared to the opening price on Friday 07/19/2024 on BTT of $66.22, this is a drop of 0.53%. Incyte Corp.'s market capitalization is $14.79 B by 224.86 M shares outstanding.
Is Incyte stock a Buy, Sell or Hold? Incyte stock has received a consensus rating of buy. The average rating score is and is based on 28 buy ratings, 25 hold ratings, and 5 sell ratings.
What was the 52-week low for Incyte stock? The low in the last 52 weeks of Incyte stock was 50.35. According to the current price, Incyte is 129.47% away from the 52-week low.
What was the 52-week high for Incyte stock? The high in the last 52 weeks of Incyte stock was 67.35. According to the current price, Incyte is 96.79% away from the 52-week high.
What are analysts forecasts for Incyte stock? The 58 analysts offering price forecasts for Incyte have a median target of 79.86, with a high estimate of 113.00 and a low estimate of 48.00. The median estimate represents a 81.63 difference from the last price of 65.19.

Incyte Stock Snapshot

56.49
Bid
2.00
Bid Size
65.20
Ask
12.00
Ask Size
7/22/2024
Date
3:59 PM
Time
0.00
Volume
65.87
Prev. Close
0.00
Open
224.86 M
Number of Shares
50.35
52 Week Low
67.35
52 Week High
65.19
0.00
Dividend in USD
0.00
Dividend Yield
23.74
P/E Ratio
98.37
Free Float in %
2.67
EPS in USD
23.14
Book Value per Share in USD
2.20
Cash Flow per Share in USD
Trade Now

Historical Prices for Incyte

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Incyte Analyst Data

Total Analysts: 58
Buy Ratings: 28 Neutral Ratings: 25 Sell Ratings: 5
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 48.00 Median: 79.86 Highest: 113.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Incyte Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
07/02/24 BMO Capital Markets
Downgraded to Sell $48
06/18/24 Cantor Fitzgerald
Maintained Hold
05/23/24 Deutsche Bank
Maintained Hold $55
05/01/24 BMO Capital Markets
Maintained Buy $52
04/24/24 Oppenheimer & Co. Inc.
Maintained Buy $84
04/23/24 Cantor Fitzgerald
Maintained Hold
03/25/24 RBC Capital Markets
Maintained Hold $65
03/13/24 Bank of America Merrill Lynch
Maintained Hold $67
03/12/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $68
03/12/24 RBC Capital Markets
Maintained Hold $65
02/23/24 Jefferies & Company Inc.
Maintained Buy $81
02/14/24 JMP Securities LLC
Downgraded to Hold
02/14/24 BMO Capital Markets
Maintained Buy $64
02/14/24 Citigroup Corp.
Maintained Buy $81
02/14/24 RBC Capital Markets
Maintained Hold $65
02/14/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $68
12/14/23 Mizuho
Maintained Hold $77
12/13/23 JMP Securities LLC
Maintained Buy $93
12/04/23 Guggenheim
Upgraded to Buy
11/21/23 Goldman Sachs
Downgraded to Hold $65
11/02/23 Goldman Sachs
Maintained Buy $98
11/01/23 RBC Capital Markets
Maintained Hold $63
11/01/23 Morgan Stanley
Maintained Hold $64
08/02/23 RBC Capital Markets
Maintained Hold $73
08/02/23 Stifel, Nicolaus & Co., Inc.
Maintained Buy $76
08/02/23 Morgan Stanley
Maintained Hold $74
08/02/23 JMP Securities LLC
Maintained Buy $93
08/02/23 BMO Capital Markets
Maintained Buy $68
08/02/23 Oppenheimer & Co. Inc.
Maintained Buy $92
07/25/23 JMP Securities LLC
Maintained Buy $93
07/25/23 Citigroup Corp.
Maintained Buy $82
07/20/23 Morgan Stanley
Maintained Sell $74
05/04/23 Bank of America Merrill Lynch
Downgraded to Hold $84
05/04/23 JMP Securities LLC
Maintained Buy $93
05/03/23 BMO Capital Markets
Maintained Buy $70
05/03/23 RBC Capital Markets
Maintained Hold $70
05/03/23 Morgan Stanley
Maintained Sell $74
05/03/23 Stifel, Nicolaus & Co., Inc.
Maintained Buy $73
05/03/23 Mizuho
Maintained Hold $82
04/19/23 JMP Securities LLC
Maintained Buy $113
04/12/23 Morgan Stanley
Maintained Hold $77
04/10/23 RBC Capital Markets
Downgraded to Hold $79
03/28/23 JMP Securities LLC
Maintained Buy $113
03/20/23 SVB Leerink
Maintained Sell $60
03/07/23 JMP Securities LLC
Maintained Buy $113
02/16/23 Credit Suisse
Maintained Buy $100
02/13/23 JMP Securities LLC
Maintained Buy $113
02/08/23 Cowen and Company, LLC
Maintained Buy $100
02/08/23 Piper Sandler
Maintained Buy $100
02/08/23 J.P. Morgan
Maintained Hold $80

Incyte Estimates* in USD

  2024 2025 2026 2027 2028
Revenue 4,083 4,494 4,921 5,288 5,585
Dividend 0.00 0.00 0.00 0.00 0.00
Dividend Yield (in %) 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
EPS 4.08 5.16 6.12 7.13 8.17
P/E Ratio 16.13 12.77 10.77 9.24 8.06
EBIT 1,078 1,383 1,661 1,758 2,048
EBITDA 1,001 1,286 1,744 1,697 2,316
Net Profit 967 - - 1,608 1,876
Net Profit Adjusted 967 - - 1,608 1,876
Pre-Tax Profit - 1,520 1,718 2,000 2,242
Net Profit (Adjusted) 1,028 1,209 1,521 1,743 2,406
EPS (Non-GAAP) ex. SOE 4.08 5.16 6.12 7.13 8.17
EPS (GAAP) 3.48 3.88 4.99 6.04 7.18
Gross Income 3,336 3,689 4,060 4,944 5,058
Cash Flow from Investing -1,330 6 13 -5 -6
Cash Flow from Operations 1,083 1,128 1,327 1,403 2,266
Cash Flow from Financing -1,330 6 13 -5 -6
Cash Flow per Share 4.46 5.47 6.83 8.72 11.40
Free Cash Flow 980 1,103 1,310 - -
Free Cash Flow per Share - - - - -
Book Value per Share 22.96 29.41 36.55 42.82 54.24
Net Debt -3,512 -4,778 -6,326 -6,202 -8,448
Research & Development Exp. 1,622 1,683 1,769 1,800 1,825
Capital Expenditure 39 69 81 15 15
Selling, General & Admin. Exp. 1,137 1,185 1,245 1,283 1,297
Shareholder’s Equity 5,246 5,938 7,137 8,697 10,778
Total Assets 6,522 7,578 8,803 10,362 12,289
  Previous Quarter
ending 06/30/24 		Current Quarter
ending 09/30/24 		Next Quarter
ending 12/31/24 		Current Year
ending 12/31/24 		Next Year
ending 12/31/25
Earnings Estimates
No. of Analysts 15 15 15 17 17
Average Estimate 0.933 USD 1.199 USD 1.318 USD 4.084 USD 5.158 USD
Year Ago 0.912 USD 0.764 USD 0.897 USD 2.672 USD -
Publish Date 7/30/2024 10/29/2024 2/13/2025 - -
Revenue Estimates
No. of Analysts 18 18 18 21 21
Average Estimate 1,011 USD 1,052 USD 1,131 USD 4,083 USD 4,494 USD
Year Ago 955 USD 919 USD 1,013 USD 3,696 USD -
Publish Date 7/30/2024 10/29/2024 2/13/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2023 2022 2021 2020 2019 2018 2017
Sales 3,695.65 3,394.64 2,986.27 2,666.70 2,158.76 1,881.88 1,536.22
Change of sales in % 8.87 13.67 11.98 23.53 14.71 22.50 38.93
Gross profit on sales 3,380.50 3,141.28 2,798.93 2,505.07 2,011.48 1,754.29 1,426.06
Gross profit on sales change in % 7.62 12.23 11.73 24.54 14.66 23.02 42.36
Operating income 651.77 599.56 637.54 -240.29 421.69 155.40 -236.03
Operating income change in % 8.71 -5.96 - - 171.36 - -
Income before tax 834.22 529.12 570.44 -232.22 486.79 115.35 -312.29
Income before tax change in % 57.66 -7.24 - - 322.02 - -
Income after tax 597.60 340.66 948.58 -295.70 446.91 109.49 -313.14
Income after tax change in % 75.42 -64.09 - - 308.16 - -

Balance Sheet in Mio. USD

2023 2022 2021 2020 2019 2018 2017
Total liabilities 1,632.48 1,513.43 1,203.73 972.49 828.34 719.80 671.95
Long-term liabilities per share 1.75 1.60 1.58 1.55 1.46 1.38 1.40
Equity 5,189.84 4,370.12 3,770.00 2,611.27 2,598.41 1,925.97 1,630.63
Equity change in % 18.76 15.92 44.37 0.49 34.91 18.11 288.74
Balance sheet total 6,822.32 5,883.55 4,973.73 3,583.76 3,426.75 2,645.76 2,302.58
Balance sheet total change in % 15.96 18.29 38.79 4.58 29.52 14.90 40.52

Key Data in USD

2023 2022 2021 2020 2019 2018 2017
Sales per share 16.36 15.16 13.45 12.23 9.92 8.73 7.51
P/E ratio (year end quote, basic EPS) 23.74 52.80 17.18 - 42.53 124.69 -
P/E ratio (year end quote, diluted EPS) 23.74 52.80 17.18 - 42.53 124.69 -
P/E ratio (year end quote) 23.74 52.80 17.18 - 42.53 124.69 -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % 76.07 74.28 75.80 72.86 75.83 72.79 70.82
Debt ratio in % 23.93 25.72 24.20 27.14 24.17 27.21 29.18

Incyte Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Flannelly Barry P 07/15/2024 1,306.00 58,042.00 64.19 Sell No
CAGNONI PABLO J 07/14/2024 749.00 221,170.00 64.25 Sell No
Iyengar Vijay K 07/14/2024 549.00 52,272.00 64.25 Sell No
Stamoulis Christiana 07/14/2024 948.00 95,197.00 64.25 Sell No
Flannelly Barry P 07/14/2024 1,111.00 59,348.00 64.25 Sell No
Hoppenot Herve 07/14/2024 4,961.00 496,674.00 64.25 Sell No
Tray Thomas 07/14/2024 466.00 25,397.00 64.25 Sell No
SWAIN PAULA J 07/14/2024 549.00 86,076.00 64.25 Sell No
Stein Steven H 07/14/2024 1,555.00 101,619.00 64.25 Sell No
CAGNONI PABLO J 07/14/2024 19,851.00 221,919.00 n/a Buy No
Iyengar Vijay K 07/14/2024 7,278.00 52,821.00 n/a Buy No
Stamoulis Christiana 07/14/2024 12,572.00 96,145.00 n/a Buy No
Flannelly Barry P 07/14/2024 9,925.00 60,459.00 n/a Buy No
Hoppenot Herve 07/14/2024 41,025.00 501,635.00 n/a Buy No
Tray Thomas 07/14/2024 5,073.00 25,863.00 n/a Buy No
Denton Sheila A. 07/14/2024 5,955.00 32,479.00 n/a Buy No
SWAIN PAULA J 07/14/2024 7,278.00 86,625.00 n/a Buy No
Trotta Matteo 07/14/2024 2,646.00 10,474.00 n/a Buy No
Stein Steven H 07/14/2024 13,895.00 103,174.00 n/a Buy No
Flannelly Barry P 07/08/2024 8,148.00 50,534.00 60.00 Sell No
Stein Steven H 07/01/2024 8,316.00 89,279.00 59.02 Sell No
Stamoulis Christiana 07/01/2024 6,870.00 83,573.00 59.02 Sell No
Clancy Paul J 06/27/2024 399.00 19,014.00 60.62 Buy No
HARRIGAN EDMUND 06/27/2024 409.00 16,354.00 60.62 Buy No
Flannelly Barry P 06/11/2024 19,164.00 66,377.00 60.00 Sell No

Incyte Dividend Calendar

Date Name Dividend *yield Currency
2023 Incyte Corp. 0.00 0.00 USD
2022 Incyte Corp. 0.00 0.00 USD
2021 Incyte Corp. 0.00 0.00 USD
2020 Incyte Corp. 0.00 0.00 USD
2019 Incyte Corp. 0.00 0.00 USD
2018 Incyte Corp. 0.00 0.00 USD
2017 Incyte Corp. 0.00 0.00 USD
2016 Incyte Corp. 0.00 0.00 USD
2015 Incyte Corp. 0.00 0.00 USD
2014 Incyte Corp. 0.00 0.00 USD
2013 Incyte Corp. 0.00 0.00 USD
2012 Incyte Corp. 0.00 0.00 USD
2011 Incyte Corp. 0.00 0.00 USD
2010 Incyte Corp. 0.00 0.00 USD
2009 Incyte Corp. 0.00 0.00 USD
*Yield of the Respective Date

Incyte Corp. Calendar

Event Estimate Info Date
Earnings Report 0.933 USD Q2 2024 Earnings Release 07/30/2024
Earnings Report 1.199 USD Q3 2024 Earnings Release 10/29/2024
Earnings Report 1.318 USD Q4 2024 Earnings Release 02/13/2025
Earnings Report 1.023 USD Q1 2025 Earnings Release 05/06/2025
Earnings Report 1.412 USD Q2 2025 Earnings Release 08/05/2025

Incyte Corp. Past Events

Event Actual EPS Info Date
Annual General Meeting - Annual General Meeting 06/12/2024

Incyte Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
3
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Incyte Shareholder

Owner in %
Freefloat 98.37
Baker Bros. Advisors LP 16.09
Baker Bros. Advisors LP 13.92
Vanguard Group, Inc. (Subfiler) 9.74
Dodge & Cox 7.16
Dodge & Cox 6.86
RBC Global Asset Management (UK) Ltd. 4.87
BlackRock Fund Advisors 4.42
State Street Corp. 4.40
Dodge & Cox Stock Fund 4.32
Vanguard Health Care Fund 3.72
Renaissance Technologies LLC 2.52
BlackRock Institutional Trust Co. NA 2.46
Vanguard Total Stock Market ETF 2.35
Geode Capital Management LLC 1.97
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Incyte Management

Name Job
Herve Hoppenot Chairman, President & Chief Executive Officer
Thomas Tray Chief Accounting Officer & Vice President-Finance
Christiana Stamoulis Chief Financial Officer & Executive Vice President
Steven H. Stein Chief Medical Officer & Executive Vice President
Vijay Iyengar EVP, Head-Global Medical Affairs & Product
Keith Mikkelson Executive Director-Business Development
Barry P Flannelly Executive VP & General Manager-North America
Michael Morrissey Executive VP & Head-Global Technical Operations
Paula J. Swain Executive Vice President-Human Resources
Lothar H. Finke Group Vice President & General Manager
Benjamin J. Strain Head-Investor Relations
Katherine A. High Independent Director
Edmund P. Harrigan Independent Director
Otis W. Brawley Independent Director
Paul J. Clancy Independent Director
Susanne Antonie Schaffert Independent Director
Jacqualyn A. Fouse Independent Director
Jean-Jacques Bienaimé Independent Director
Julian Charles Baker Lead Independent Director
Pablo J. Cagnoni President-Research & Development
Sheila A. Denton Secretary, Executive VP & General Counsel
Peter Langmuir Vice President-Oncology Drug Development